Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Educational Materials · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Educational Materials | PROCEDURE | - |
Inclusion Criteria: * Male and female, age \> = 18 years and \<= 80 years with a diagnosis of type 2 diabetes made at least 6 months prior to study entry * Currently treated with either: * 2 or more oral antidiabetic agents, OR 1 or more oral antidiabetic agents and insulin glargine Exclusion Crit...
Educational Materials is an investigational product being studied for use in Diabetes Mellitus, Type 2. It is currently in Phase 3 clinical development. The product is being developed by Pfizer, Inc. (PFE) for the metabolic therapeutic area.
Pfizer, Inc. (PFE) is developing Educational Materials. The product is being studied for the treatment of Diabetes Mellitus, Type 2 and is currently in Phase 3 clinical development.
Educational Materials is in Phase 3 clinical development. It is an investigational product being studied for Diabetes Mellitus, Type 2. It has not been approved by regulatory authorities and remains in clinical trials.
Educational Materials is associated with one completed Phase 3 clinical trial, NCT00139763, titled 'US Inhaled Insulin Therapeutic Choice Questionnaire Study'. This trial enrolled 740 participants with Diabetes Mellitus, Type 2 in the United States.
Educational Materials is not FDA approved. It is an investigational product in Phase 3 clinical development for Diabetes Mellitus, Type 2. The associated clinical trial, NCT00139763, has been completed, but regulatory approval has not been granted.